Immunic ( (IMUX) ) just unveiled an announcement.
On September 9, 2026, Immunic hosted a Relapsing Multiple Sclerosis Research and Development Day webinar to present updates on its RMS program via a video conference held from 11:00 a.m. to 12:30 p.m. ET. The event highlighted the company’s development strategy around vidofludimus calcium, including its potential progression into a confirmatory phase 3 trial in progressive multiple sclerosis and broader implications for Immunic’s clinical pipeline, regulatory trajectory, and Nasdaq listing status, while underscoring substantial risks and uncertainties around financing, trial outcomes, and market conditions.
Management emphasized that these updates reflect current expectations and are subject to factors such as macroeconomic pressures, geopolitical conflicts affecting clinical trials, regulatory risks, intellectual property protection, and competition. The company cautioned that actual results may differ materially from these projections, signaling ongoing uncertainty for investors and other stakeholders regarding future operations, cash resources, and the ultimate commercial potential of its product candidates.
The most recent analyst rating on (IMUX) stock is a Buy
with a $27.00 price target.
To see the full list of analyst forecasts on Immunic stock,
see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.
IMUX scores below average primarily due to very weak financial performance (no revenue, large losses, and high cash burn), which outweighs the balance-sheet benefit of low debt and improved equity. Technical indicators are mostly neutral with slight near-term weakness, while valuation is constrained by negative earnings and no dividend support. Corporate events are a modest offset, highlighted by strengthened leadership/governance and positive MS data updates, but dilution risk remains.
To see Spark’s full report on IMUX stock,
click here.
More about Immunic
Immunic, Inc. is a biopharmaceutical company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, with a particular emphasis on multiple sclerosis. Its pipeline includes vidofludimus calcium, which targets immune-mediated conditions and is being evaluated for its potential safety and efficacy across several indications.
Average Trading Volume: 200,058
Technical Sentiment Signal: Sell
Current Market Cap: $178.9M
For a thorough assessment of IMUX stock, go to TipRanks’ Stock Analysis page.